Dainippon Pharmaceut (DNPUF) 12.7000 $DNPUF Multiple

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dainippon Pharmaceut (DNPUF) 12.7000 $DNPUF

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.63 (+0.02), DRNA: 3.24 (-0.06), INCY: 88.16 (+0.04), LLY: 82.99 (+0.06), STML: 7.62 (+0.17), SNTA: 0.34 (+0.07), ANTH: 3.06 (unch), EXEL: 9.07 (+0.12)

World Thymus Cancer Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/chmdh8/thymus_cancer) has announced the addition of the "Thymus Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thymus Cancer Overview - Therapeutics Development - Pipeline Products for Thymus Cancer - Overview - Pipeline Products for Thymus Cancer - Comparative Analysis - Thymus Cancer - Therapeutics under Development by Companies - Thymus Cancer - Therapeutics under Investigation by Universities/Institutes - Thymus Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thymus Cancer - Products under Development by Companies - Thymus Cancer - Products under Investigation by Universities/Institutes - Thymus Cancer - Companies Involved in Therapeutics Development - Cellceutix Corporation - Merck & Co., Inc. - Novartis AG - Onxeo SA - Sumitomo Dainippon Pharma Co., Ltd. - Tiziana Life Sciences Plc For more information visit http://www.researchandmarkets.com/research/ch...mus_cancer
MRK: 58.70 (+0.27), NVS: 83.18 (+1.10)

Klebsiella Pneumoniae Infections Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdwshp/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Klebsiella Pneumoniae Infections Overview - Therapeutics Development - Pipeline Products for Klebsiella Pneumoniae Infections - Overview - Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis - Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies - Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Klebsiella Pneumoniae Infections - Products under Development by Companies - Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Boehringer Ingelheim GmbH - Cellceutix Corporation - Debiopharm International S.A. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/xdwshp/klebsiella
TTPH: 4.10 (+0.02), SRPT: 24.97 (+0.31), PFE: 36.85 (+0.18), MRK: 58.70 (+0.27)

Global Soft Tissue Sarcoma Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/thz6jx/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Soft Tissue Sarcoma Overview - Therapeutics Development - Pipeline Products for Soft Tissue Sarcoma - Overview - Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis - Soft Tissue Sarcoma - Therapeutics under Development by Companies - Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Soft Tissue Sarcoma - Products under Development by Companies - Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Amgen Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - CASI Pharmaceuticals Inc. - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Double Bond Pharmaceutical International AB - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gem Pharmaceuticals, LLC - GlaxoSmithKline Plc - Lytix Biopharma AS - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Noxxon Pharma AG - OncoTherapy Science, Inc. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Philogen S.p.A. - Plexxikon Inc. - Siena Biotech S.p.A. - Sigma-Tau S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. - Targovax AS For more information visit http://www.researchandmarkets.com/research/th...oft_tissue
CLRB: 2.83 (-0.03), PFE: 36.85 (+0.18), AMGN: 171.79 (+0.51), LLY: 82.99 (+0.06), EPZM: 10.38 (+0.12), GSK: 45.27 (+0.09), CASI: 1.12 (-0.04), MACK: 5.85 (+0.24), MRK: 58.70 (+0.27), CYTR: 0.63 (+0.01), NVS: 83.18 (+1.10), CELGZ: 1.17 (-0.02), EXEL: 9.07 (+0.12)

Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 125.08 (+0.62), NBIX: 50.11 (-0.04), KMPH: 4.16 (+0.13), ZGNX: 9.13 (+0.05), PFE: 36.85 (+0.18), AZN: 34.17 (-0.12), TEVA: 53.77 (-1.02), ITCI: 40.98 (+0.01), OMER: 11.86 (+0.16)

Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 171.79 (+0.51), ATRA: 24.02 (-0.03), STML: 7.62 (+0.17), SNTA: 0.34 (+0.07), ATNM: 1.75 (unch), SNDX: 12.30 (+0.13), BLCM: 15.90 (+0.15), BPTH: 1.73 (-0.01), TEVA: 53.77 (-1.02), AGIO: 44.78 (+0.92), XLRN: 33.96 (+0.03), ARRY: 3.78 (+0.01)

World Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/w7bf8s/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview - Therapeutics Development - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - ContraFect Corporation - Debiopharm International S.A. - ImmuVen, Inc. - Lytix Biopharma AS - PharmaIN Corporation - Sealife PHARMA GMBH - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/w7...llinsuscep

Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 36.85 (+0.18), VBAY: (), BMY: 74.58 (-0.08), LPTN: 2.01 (+0.01), OMER: 11.86 (+0.16), CUR: 0.24 (unch), CELGZ: 1.17 (-0.02)

Streptococcus Pneumoniae Infection Therapeutic Developments Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/klpqfj/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Streptococcus Pneumoniae Infection Overview - Therapeutics Development - Pipeline Products for Streptococcus Pneumoniae Infection - Overview - Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis - Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Streptococcus Pneumoniae Infection - Products under Development by Companies - Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development - Abera Bioscience AB - Allergan Plc - Alvogen Korea - Arsanis Biosciences GmbH - AstraZeneca Plc - Beijing Minhai Biotechnology Co., Ltd - ContraFect Corporation - Daiichi Sankyo Company, Limited - Eurocine Vaccines AB - FluGen, Inc. - GlaxoSmithKline Plc - ImmunoBiology Limited - Lascco SA - Liquidia Technologies, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Mucosis B.V. - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Valneva SE - Vaxxilon AG - Virometix AG - Walvax Biotechnology Co., Ltd. - Wellstat Vaccines, LLC - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/kl...eptococcus
AGN: 254.98 (-0.58), MRK: 58.70 (+0.27), AZN: 34.17 (-0.12), GSK: 45.27 (+0.09), SVA: 5.88 (+0.03)

Irritable Bowel Syndrome - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2k9l4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identifies emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develops strategic initiatives by understanding the focus areas of leading companies - To identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome - To plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4D Pharma Plc - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allergan Plc - Ardelyx, Inc. - Astellas Pharma Inc. - CJ HealthCare Corp. - Dong-A Socio Group - Enterome Bioscience SA - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - SK Biopharmaceuticals Co., Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/n2...able_bowel
SGYP: 4.11 (unch), AGN: 254.98 (-0.58), SYN: 1.78 (unch), IRWD: 14.14 (-0.20), PFE: 36.85 (+0.18)

Enterococcus Faecium Infections - Global Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzzqvp/enterococcus) has announced the addition of the "Enterococcus faecium Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Enterococcus Faecium Infections Overview - Therapeutics Development - Pipeline Products for Enterococcus Faecium Infections - Overview - Pipeline Products for Enterococcus Faecium Infections - Comparative Analysis - Enterococcus Faecium Infections - Therapeutics under Development by Companies - Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Enterococcus Faecium Infections - Products under Development by Companies - Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen Korea - Aphios Corporation - BioSource Pharm, Inc. - Cellceutix Corporation - ContraFect Corporation - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rz...terococcus
OGEN: 0.72 (unch)

World Psychosis Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/255wj4/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Psychosis Overview - Therapeutics Development - Pipeline Products for Psychosis - Overview - Pipeline Products for Psychosis - Comparative Analysis - Psychosis - Therapeutics under Development by Companies - Psychosis - Therapeutics under Investigation by Universities/Institutes - Psychosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psychosis - Products under Development by Companies - Psychosis - Products under Investigation by Universities/Institutes - Psychosis - Companies Involved in Therapeutics Development - Acadia Pharmaceuticals Inc. - Addex Therapeutics Ltd - Eli Lilly and Company - Evotec AG - Gabather AB - Glenmark Pharmaceuticals Ltd. - Heptares Therapeutics Limited - Integrative Research Laboratories Sweden AB - Newron Pharmaceuticals S.p.A. - Reviva Pharmaceuticals Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/255wj4/psychosis
ACAD: 36.81 (+0.07), LLY: 82.99 (+0.06)

Lewy body Dementia Pipeline Review, H2 2015 - Analysis, Technologies, Trends & Forecasts
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/r7q53h/lewy_body) has announced the addition of the "Lewy body Dementia - Pipeline Review, H2 2015" report to their offering. The report Lewy body Dementia - Pipeline Review, H2 2015', provides an overview of the Lewy body Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Scope: - The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lewy body Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lewy body Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics Companies Mentioned: - Addex Therapeutics Ltd - Axovant Sciences Ltd. - BioArctic Neuroscience AB - Neuropore Therapies, Inc. - ProteoTech, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/r7q53h/lewy_body
AXON: 14.64 (+0.04)

Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 7.67 (-0.23), NWBO: 0.43 (-0.02)

Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 82.99 (+0.06), BMY: 74.58 (-0.08), GSK: 45.27 (+0.09), ALKS: 49.32 (+1.19), AGN: 254.98 (-0.58), CERCU: 5.03 (-0.56), JNJ: 125.08 (+0.62), ITCI: 40.98 (+0.01), CUR: 0.24 (unch)

Sumitomo Dainippon Pharma Co., Ltd. Industry - Global Product Pipeline Review - 2015
M2 - Wed Dec 16, 4:35AM CST
Summary

Sunovion Celebrates Five-Year Anniversary Milestone
BusinessWire - Thu Oct 15, 9:00AM CDT
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion's parent company Sumitomo Dainippon Pharma Co., Ltd. Over the course of five years, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.

Streptococcus Pyogenes Infections Pipeline Review, H2 2015 - 6 Companies & 10 Drug Profiles
M2 - Mon Oct 05, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxmsnq/streptococcus) has announced the addition of the "Streptococcus Pyogenes Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Aureogen Biosciences, Inc. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Wellstat Vaccines, LLC Drug Profiles - BMY-28117 - HB-1345 - SM-295291 - SM-369926 - Small Molecules to Inhibit DHFR for Infectious Diseases - Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - streptococcus [serotype A] vaccine - streptococcus polysaccharide [serotype A] vaccine - streptococcus pyogenes vaccine - streptococcus pyogenes vaccine (30-valent) For more information visit http://www.researchandmarkets.com/research/px...eptococcus
GSK: 45.27 (+0.09)

Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 254.98 (-0.58), VRTX: 96.08 (-0.13), SRPT: 24.97 (+0.31), GSK: 45.27 (+0.09)

Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 83.18 (+1.10)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 65

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 243

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 14

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 445

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 44

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 24

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading

Top 5 Most Recently Viewed Articles

STREAM Foundation Joins Forces with Greenwood Project for Growth

Updated Category News Views 138

STREAM Foundation Announces Exciting Collaboration The STREAM Foundation is thrilled to announce its upcoming merger with the Greenwood Project, a nationally renowned nonprofit dedicated to enhancing career pathways for underrepresented students. This strategic merger will significantly expand the breadth of resources and opportunities available to students interested in...

Continue Reading
Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 264

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Top Precious Metal Stocks Impress Investors Amid Gold Surge

Updated Category News Views 326

Introduction to Precious Metals Stocks October has proven to be a prosperous month for precious metals stocks as they ascend into the upper echelons of market momentum rankings. This surge is primarily attributed to increased global demand, which is simultaneously boosting gold prices and favoring the miners’ positions. Gold's Resurgence Fuels Stock Momentum The recent...

Continue Reading
XTI Aerospace's Strategic Advancements and Financial Highlights

Updated Category News Views 156

XTI Aerospace's Significant Progress in Q3 2025 XTI Aerospace, Inc. (NASDAQ: XTIA) has made remarkable strides as a leader in vertical flight technologies. The company's innovative TriFan 600 aircraft is set to revolutionize commercial and defense aerospace applications. Recently, XTI announced its impressive achievements for the third quarter of 2025, marking a period...

Continue Reading